These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11409909)

  • 1. Laboratory correlates in multiple myeloma: how useful for prognosis?
    Fonseca R; Conte G; Greipp PR
    Blood Rev; 2001 Jun; 15(2):97-102. PubMed ID: 11409909
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic indicators for the diagnosis of multiple myeloma.
    Greipp P;
    Oncology (Williston Park); 2004 May; 18(5):558-60. PubMed ID: 15209186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple myeloma: new staging systems for diagnosis, prognosis and response evaluation.
    Rajkumar SV; Buadi F
    Best Pract Res Clin Haematol; 2007 Dec; 20(4):665-80. PubMed ID: 18070712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The significance and current diagnostic options of cytogenetic changes in multiple myeloma].
    Kuglík P; Filková H; Oltová A; Hájek R
    Vnitr Lek; 2006 Nov; 52 Suppl 2():76-8. PubMed ID: 18175433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A modified cytogenetic study for multiple myeloma].
    Qin YW; Wei DL; Wang C; Yan SK; Gao YR; Cai Q
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2006 Apr; 23(2):213-5. PubMed ID: 16604501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM
    Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of molecular diagnostics in multiple myeloma.
    Stewart AK; Fonseca R
    Expert Rev Mol Diagn; 2007 Jul; 7(4):453-9. PubMed ID: 17620051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [To promote the process of standardized molecular cytogenetic testing for multiple myeloma].
    Chen LJ; Qu XY; Li JY
    Zhonghua Xue Ye Xue Za Zhi; 2013 Apr; 34(4):290-1. PubMed ID: 23668195
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical use of genomics in multiple myeloma.
    Shaughnessy JD
    Clin Adv Hematol Oncol; 2006 Jun; 4(6):419-21. PubMed ID: 16981662
    [No Abstract]   [Full Text] [Related]  

  • 11. International Staging System required standardization of biochemical laboratory testing in multiple myeloma.
    Tichý M; Maisnar V; Palicka V; Friedecký B; Vávrová J; Novotná H; Cermáková Z; Dastych M; Cechák P; Vogtová D; Jarolímková E; Benáková H; Hachová L; Bezdícková D; Kouril F; Zábranská EA; Zenková J; Slabý P; Scudla V; Gregora E; Spicka I; Straub J; Schützova M; Hájek R
    Neoplasma; 2006; 53(6):492-4. PubMed ID: 17167717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case study of intracerebral plasmacytoma as an initial presentation of multiple myeloma.
    Wavre A; Baur AS; Betz M; Mühlematter D; Jotterand M; Zaman K; Ketterer N
    Neuro Oncol; 2007 Jul; 9(3):370-2. PubMed ID: 17522337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cell kinetics of multiple myeloma.
    Boccadoro M; Pileri A
    Hematol Pathol; 1987; 1(3):137-42. PubMed ID: 3334345
    [No Abstract]   [Full Text] [Related]  

  • 14. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management?
    Tassone P; Tagliaferri P; Rossi M; Gaspari M; Terracciano R; Venuta S
    Eur J Cancer; 2006 Jul; 42(11):1530-8. PubMed ID: 16820292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma.
    Hungria VT; Maiolino A; Martinez G; Colleoni GW; Coelho EO; Rocha L; Nunes R; Bittencourt R; Oliveira LC; Faria RM; Pasquini R; Magalhães SM; Souza CA; Pinto Neto JV; Barreto L; Andrade E; Portella Mdo S; Bolejack V; Durie BG;
    Haematologica; 2008 May; 93(5):791-2. PubMed ID: 18450738
    [No Abstract]   [Full Text] [Related]  

  • 16. Economical choices in setting up a diagnostic myeloma laboratory.
    Anand M; Kumar R; Sharma OD
    Indian J Pathol Microbiol; 2004 Oct; 47(4):506-8. PubMed ID: 16295377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor.
    Vela-Ojeda J; García-Ruiz Esparza MA; Padilla-González Y; Sánchez-Cortes E; García-Chávez J; Montiel-Cervantes L; Reyes-Maldonado E; Majluf-Cruz A; Mayani H
    Ann Hematol; 2009 Jan; 88(1):59-66. PubMed ID: 18648809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone marrow angiogenesis and angiogenic factors in multiple myeloma treated with novel agents.
    Cibeira MT; Rozman M; Segarra M; Lozano E; Rosiñol L; Cid MC; Filella X; Bladé J
    Cytokine; 2008 Mar; 41(3):244-53. PubMed ID: 18178097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional cytogenetics in myeloma.
    Campbell LJ
    Methods Mol Med; 2005; 113():37-47. PubMed ID: 15968093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors and staging in multiple myeloma.
    Fonseca R; San Miguel J
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1115-40, ix. PubMed ID: 17996591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.